LeonaBio is a recycled Athira vehicle that licensed a late-stage oral estrogen-receptor drug for mutant metastatic breast cancer, financed the purchase with a sponsor-led private placement, and now trades as a going-concern option on a single unfinished registrational study because cash on hand is already too thin to reach the data.
The load-bearing event is the December license from Sermonix Pharmaceuticals, which moved Western development of lasofoxifene into the old Athira legal entity in exchange for a near-zero-strike pre-funded warrant, back-end commercialization milestones, and a thin royalty, while a concurrent private placement co-led by Commodore Capital, Perceptive Advisors, and TCGX put $90 million of common stock and warrants onto the balance sheet. That structure let the company take over a more-than-half-enrolled registrational program without writing a large cash check to the licensor, which is why the January rename to LeonaBio and the ticker switch followed within weeks. The residual claim now lives or dies with blinded progression-free survival in the inherited combination study, not with the old ALS and Alzheimer programs that emptied the prior franchise.
The tension is that the same company that advertised a multi-year runway now states that cash and investments of $51 million at mid-year may not cover twelve months of operations. Operating spend has jumped because the inherited trial is expensive, the simplified shelf stays blocked into year-end, and the large cash-exercise warrant package does not become exercisable until late autumn, so the advertised backstop is not yet live. Shareholders are underwriting a registrational burn with a cash pile that already sits inside a going-concern paragraph.
The near-term resolution is enrollment completion late this year and the first real test of whether Series A warrant holders exercise for cash once those warrants unlock, because only that combination funds the study through a latter-half data print in the following calendar year.